Grants and Contributions:
Title:
Small molecule drug development for COVID
Agreement Number:
973631
Agreement Value:
$49,337.00
Agreement Date:
Jun 1, 2021 - Jul 31, 2024
Description:
Using a bioassay guided fractionation method, AffinityImmuno identified a natural product that is a potent inhibitor of SARS-CoV-2 spike protein binding to ACE2. Research on this natural product is to be accelerated and tested in an series of SARS-CoV-2 permissible cell lines and a hamster model of Covid-19 in order to determine whether to pursue a human health product.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Brackley, Prince Edward Island, CA C1E 1C4
Reference Number:
172-2021-2022-Q1-973631
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
807019971
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 762 days.
Amendment Date
Jun 28, 2022
Recipient's Legal Name:
AffinityImmuno Inc.
Federal Riding Name:
Malpeque
Federal Riding Number:
11004
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: